Knocking down FTO in melanoma enhances sensitivity to anti-PD-1 and IFN therapies by suppressing PD-1 (PDCD1), CXCR4, and SOX10 expression through YTHDF2-mediated mRNA decay, but it does not affect PD-L1 (CD274).112. The gene discussed is CD274; the disease is melanoma.